Inactivation and activation of various membranal enzymes of the cholesterol biosynthetic pathway by digitonin.
The activity of rat liver microsomal squalene epoxidase is inhibited effectively by digitonin. Concentrations of 0.8 to 1.2 mg/ml of digitonin cause total inhibition of microsomal (0.75 mg protein/ml) squalene epoxidase either in microsomes that were pretreated with digitonin and subsequently washed and subjected to epoxidase assay or when digitonin was added directly to the assay. The inhibition of squalene epoxidase by digitonin is concentration-dependent and takes place rapidly within 5 min of exposure of the microsomes to digitonin. Octylglucoside, dimethylsulfoxide, CHAPS, as well as cholesterol or total microsomal lipid extract were ineffective in restoring the digitonin-inhibited squalene epoxidase activity. Epoxidase activity in digitonin-treated microsomes was fully restored by Triton X-100. The reactivation by Triton X-100 displays a concentration optimum with maximal reactivation of the epoxidase (0.7 mg protein/ml) occurring at 0.2% Triton X-100. Microsomal 2,3-oxidosqualene-lanosterol cyclase is also inhibited by digitonin. Higher concentrations of digitonin are required to obtain full inhibition of the cyclase activity and only 40% inhibition of cyclase activity is observed at 1 mg/ml of digitonin. Solubilized (subunit size 55 to 66 kDa) and microsomal (subunit size 97 kDa) 3-hydroxy-3-methylglutaryl CoA reductase are totally unaffected by the same concentration of digitonin. Squalene synthetase, another microsomal enzyme in the biosynthetic pathway of cholesterol, is activated by digitonin. A 2.2-fold activation of squalene synthetase is observed at 0.8 mg/ml of digitonin. The results agree with a model in which squalene, and to a lesser degree 2,3-oxidosqualene, are segregated by digitonin into separate intramembranal pools.(ABSTRACT TRUNCATED AT 250 WORDS)
Eilenberg
H
H
Department of Biochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.
Klinger
E
E
Przedecki
F
F
Shechter
I
I
D000818:Animals; D002784:Cholesterol / Q000096:biosynthesis*; D004072:Digitonin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D004793:Enzyme Reactivators; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000378:metabolism*; D007425:Intracellular Membranes / Q000187:drug effects / Q000201:enzymology*; D019751:Intramolecular Transferases; D007535:Isomerases / Q000037:antagonists & inhibitors*; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology*; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism; D017830:Octoxynol; D010088:Oxidoreductases / Q000378:metabolism*; D010105:Oxygenases / Q000037:antagonists & inhibitors*; D011092:Polyethylene Glycols; D051381:Rats; D050603:Squalene Monooxygenase
D004793:Enzyme Reactivators; D011092:Polyethylene Glycols; D017830:Octoxynol; D002784:Cholesterol; D010088:Oxidoreductases; D010105:Oxygenases; D050603:Squalene Monooxygenase; D009251:NADPH-Ferrihemoprotein Reductase; D013186:Farnesyl-Diphosphate Farnesyltransferase; D007535:Isomerases; D019751:Intramolecular Transferases; C021924:lanosterol synthase; D004072:Digitonin